Observational Study With Enbrel in Patients With Rheumatoid Arthritis

Wyeth is now a wholly owned subsidiary of Pfizer0 sites1,500 target enrollmentJune 2003

ConditionsRheumatoid Arthritis

DrugsEnbrel

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Rheumatoid Arthritis
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 1500
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection site reactions based on whether health care professionals or patients administer Enbrel will be assessed and evaluated.

Registry

clinicaltrials.gov

Start Date

June 2003

End Date

July 2005

Last Updated

18 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•Proven diagnosis of rheumatoid arthritis

Exclusion Criteria

•Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation:
•Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®
•Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections
•Patients with sepsis or risk of sepsis should not be treated